
Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Indication, Route of administration, Age Group - Global Forecast 2024-2030
Description
Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Indication, Route of administration, Age Group - Global Forecast 2024-2030
The Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024, at a CAGR 7.79% to reach USD 94.14 billion by 2030.
Global Vaccines Market
Vaccines are biological preparations that equip the body's immune system with the capability to combat disease-causing microbes effectively. They work by stimulating the immune response to generate a specific defense mechanism, predominantly in the form of antibodies, against harmful pathogens. The rising incidence of infectious diseases globally and the rise in immunization programs worldwide significantly influence this growth. Moreover, favorable government initiatives and policies for vaccine development are also driving market growth. High development costs, lengthy testing and approval process issues over product recalls, and inaccessibility in a few regions pose challenges to the growth of the vaccine market. Integration of adjuvants in vaccines, development of therapeutic vaccines, and growth in the contract manufacturing of the vaccines are expected to create significant growth opportunities in the market.
Regional Insights
In Asia-Pacific, robust economies such as China, India, and Japan have exhibited significant growth in vaccine markets due to large population densities and high prevalence of infectious diseases, necessitating comprehensive immunization drives. There's a high need for vaccines in the Americas, comprising countries such as the United States and Canada, owing to the demographic makeup and an expansive public health infrastructure. Significant investments in research and development (R&D) of vaccines, recent patents, and initiatives further fuel the growth. The EMEA region, with diverse economic landscapes, displays varying consumer behavior. The European Union, with well-funded health systems, necessitates extensive immunization programs. The Middle East and Africa possess a significant potential for market growth. Initiatives such as the collaboration between the Serum Institute of India and the Africa Vaccine Acquisition Trust in 2022 to supply COVID-19 vaccines are pivotal changes reshaping this landscape.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co.,Ltd., CSL Limited, CureVac SE, Daiichi Sankyo Co., Ltd., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mitsubishi Chemical Group Corporation, Moderna Inc., Novavax, Inc., Pfizer Inc., Sanofi Group, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.
Market Segmentation & Coverage
This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Monovalent Vaccine
Multivalent Vaccine
Technology Type
Inactivated Vaccines
Live-Attenuated Vaccines
Messenger RNA (mRNA) Vaccines
Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
Toxoid Vaccines
Viral Vector Vaccines
Indication
DPT
Hepatitis
Human Papillomavirus
Influenza
Measles
Meningococcal Disease
Mumps & Rubella
Pneumococcal Disease
Polio
Rotavirus
Varicella
Route of administration
Intramuscular & Subcutaneous
Oral
Age Group
Adults
Pediatric
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Vaccines Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccines Market?
3. What are the technology trends and regulatory frameworks in the Vaccines Market?
4. What is the market share of the leading vendors in the Vaccines Market?
5. Which modes and strategic moves are suitable for entering the Vaccines Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Vaccines Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence of infectious diseases globally
- 5.1.1.2. Favorable government initiatives and policies for vaccine development
- 5.1.1.3. Growing focus on immunization across the world
- 5.1.2. Restraints
- 5.1.2.1. High development costs, lengthy testing and approval processes
- 5.1.3. Opportunities
- 5.1.3.1. Integration of adjuvants in vaccines and development of therapeutic vaccines
- 5.1.3.2. Growth in the contract manufacturing of the vaccines
- 5.1.4. Challenges
- 5.1.4.1. Issues over product recalls and inaccessibility in few regions
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Significant preference for monovalent vaccines for specific disease prevention
- 5.2.2. Technology Type: Rising development in the conjugate vaccines as an viable alternative
- 5.2.3. Indication: Growing need for DPT vaccine for protection against serious respiratory ailments
- 5.2.4. Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses
- 5.2.5. Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Vaccines Market, by Type
- 6.1. Introduction
- 6.2. Monovalent Vaccine
- 6.3. Multivalent Vaccine
- 7. Vaccines Market, by Technology Type
- 7.1. Introduction
- 7.2. Inactivated Vaccines
- 7.3. Live-Attenuated Vaccines
- 7.4. Messenger RNA (mRNA) Vaccines
- 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
- 7.6. Toxoid Vaccines
- 7.7. Viral Vector Vaccines
- 8. Vaccines Market, by Indication
- 8.1. Introduction
- 8.2. DPT
- 8.3. Hepatitis
- 8.4. Human Papillomavirus
- 8.5. Influenza
- 8.6. Measles
- 8.7. Meningococcal Disease
- 8.8. Mumps & Rubella
- 8.9. Pneumococcal Disease
- 8.10. Polio
- 8.11. Rotavirus
- 8.12. Varicella
- 9. Vaccines Market, by Route of administration
- 9.1. Introduction
- 9.2. Intramuscular & Subcutaneous
- 9.3. Oral
- 10. Vaccines Market, by Age Group
- 10.1. Introduction
- 10.2. Adults
- 10.3. Pediatric
- 11. Americas Vaccines Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Vaccines Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Vaccines Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. FPNV Positioning Matrix
- 14.2. Market Share Analysis, By Key Player
- 14.3. Competitive Scenario Analysis, By Key Player
- 14.3.1. Agreement, Collaboration, & Partnership
- 14.3.1.1. BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
- 14.3.2. Award, Recognition, & Expansion
- 14.3.2.1. Oxford R21/Matrix-M Malaria Vaccine Receives WHO Recommendation for Use
- 14.3.2.2. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories
- 15.1.2. Astellas Pharma Inc.
- 15.1.3. AstraZeneca PLC
- 15.1.4. Bavarian Nordic A/S
- 15.1.5. Bharat Biotech Ltd.
- 15.1.6. Biological E. Limited
- 15.1.7. Chongqing Zhifei Biological Products Co.,Ltd.
- 15.1.8. CSL Limited
- 15.1.9. CureVac SE
- 15.1.10. Daiichi Sankyo Co., Ltd.
- 15.1.11. Emergent BioSolutions Inc.
- 15.1.12. Gennova Biopharmaceuticals Limited
- 15.1.13. GlaxoSmithKline PLC
- 15.1.14. Inovio Pharmaceuticals, Inc.
- 15.1.15. Johnson & Johnson Services, Inc.
- 15.1.16. Merck KGaA
- 15.1.17. Mitsubishi Chemical Group Corporation
- 15.1.18. Moderna Inc.
- 15.1.19. Novavax, Inc.
- 15.1.20. Pfizer Inc.
- 15.1.21. Sanofi Group
- 15.1.22. Serum Institute of India Pvt. Ltd.
- 15.1.23. Sinovac Biotech Ltd.
- 15.1.24. Takeda Pharmaceutical Company Limited
- 15.1.25. Zydus Lifesciences Limited
- 15.2. Key Product Portfolio
- 16. Appendix
- 16.1. Discussion Guide
- 16.2. License & Pricing
- FIGURE 1. VACCINES MARKET RESEARCH PROCESS
- FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
- FIGURE 3. VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. VACCINES MARKET DYNAMICS
- FIGURE 7. VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
- FIGURE 10. VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 14. VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
- FIGURE 16. VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 20. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 26. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.